Development of Products. (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.
Development of Products. 37 4.1 Responsibilities of the Parties .......................................... 37 4.2
Development of Products. 4.1 During the Research Term, Orasense will diligently pursue the research and development of the Elan Intellectual Property, Isis Intellectual Property and Orasense Technology in accordance with the Research and Development Program. The objectives of this initial phase of the Research and Development Program will be (a) to develop the Oral Platform, and (b) to develop the Development Product.
Development of Products. 28 3.5. Laboratory Facilities and Personnel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Development of Products. Lilly will in its discretion determine which, if any, such Hit(s), or Derivative(s) of Hit(s), will be approved as an Approved PTAC Compound. Lilly will be responsible for all pre-clinical and clinical development, including all regulatory filings, of Hits and Approved PTAC Compounds arising out of this Agreement. Lilly shall have discretion and control over the conduct of, and all activities associated with, the development or abandonment of any Approved *** CONFIDENTIAL TREATMENT REQUESTED
Development of Products. Rockford and Path will cooperate to improve existing Products and develop new Products that will satisfy the needs of Rockford's Dealers, and their customers. Path is principally responsible for development of (*) CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL MATERIAL HAS BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION. 5 improvements to existing Products and new Products. Before the development of new or improved Products the parties will meet and agree upon:
Development of Products. BMS will in its sole and absolute discretion determine which, if any, such Hit(s) will be approved as Lead Compounds and developed further in a Lead Compound Development Program conducted by BMS. BMS shall be responsible for all pre-clinical (including medicinal chemistry) activities during the course of the Lead Compound Development Program for such Lead Compound, as well as following any approval of an Approved PLP Compound. The conduct of the Lead Compound Development Program shall be solely within the control and discretion of BMS, and BMS may in its discretion suspend or terminate, in whole or in part, the Lead Compound Development Program for a Lead Compound at any time. BMS will be responsible for all pre-clinical and clinical development, including all regulatory filings, of Hits, Lead Compounds, and Approved PLP Compounds arising out of this Agreement. BMS shall have sole and absolute discretion and control over the conduct of, and all activities associated with, the development or abandonment of any Hit or Lead Compound, the approval of a Lead Compound as an Approved PLP Compound, the development or abandonment of any Approved PLP Compound, all regulatory activities relating to the manufacture, use or sale of any Approved PLP Compound or Product, and the commercialization and marketing of any Product in any country. All INDs, NDAs and other regulatory filings made or filed by BMS for any Approved PLP Compound or Product shall be owned solely by BMS. BMS will provide summary annual reports to Aurora on the development status of any Approved PLP Compound then in development arising out of the ESP Screening Program and which shall *** CONFIDENTIAL TREATMENT REQUESTED 35 39 be treated as BMS Confidential Information hereunder. Other than royalty reports required hereunder, no reports shall be required of BMS with respect to any activities connected with the commercialization of any Product approved for marketing in any country.
Development of Products. 13 5 REGULATORY APPROVALS................................................................13
Development of Products. Senomyx will be responsible, at Senomyx's expense, for all formulation and regulatory approval of Products arising out of this Agreement. Senomyx shall use reasonable efforts, consistent with commercial business practices, to develop any Product, to perform all regulatory activities relating to the manufacture, use or sale of any Product, and to commercialize and market any Product in any country. All regulatory filings made or filed by Senomyx for any Development Compound or Product shall be owned solely by Senomyx. At Senomyx's request and expense, Aurora shall cooperate to the extent reasonably necessary to permit Senomyx to perform the foregoing activities.
Development of Products. 4.1 During the Research and Development Term, Newco will diligently pursue the research and development of the Elan Intellectual Property, TGEN Intellectual Property and Newco Technology in accordance with the Research and Development Program. The objectives of this research and development work will be (a) to develop the Platform, and (b) to develop one or more Products in the Field.
